Journals / Turkish Journal of Gastroenterology / 2011 / Cilt: 22 - Sayı: 1

Kronik hepatit C hastalarında serum ileri oksidasyon protein ürünleri, malonildialdehid ve total radikal tutucu antioksidan parametre düzeyleri

Serum levels of advanced oxidation protein products, malonyldialdehyde, and total radical trapping antioxidant parameter in patients with chronic hepatitis C

Pages
47–53
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Serum levels of advanced oxidation protein products and malonyldialdehyde are higher in chronic hepatitis C patients when compared to healthy individuals, and may be useful markers in chronic hepatitis C.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims: Oxidative stress increases in chronic hepatitis C, and antioxidant defense mechanisms are impaired.
📊
Key Findings & Data:Twenty-nine biopsy-proven chronic hepatitis C patients, with no prior anti-viral treatment and persistently elevated serum transaminase levels for 6 months, were included.
💡
Conclusion & Impact:Serum levels of advanced oxidation protein products and malonyldialdehyde are higher in chronic hepatitis C patients when compared to healthy individuals, and may be useful markers in chronic hepatitis C.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aims: Oxidative stress increases in chronic hepatitis C, and antioxidant defense mechanisms are impaired. The aims of this study were to compare chronic hepatitis C patients and healthy subjects according to oxidative stress and antioxidant system markers, and to determine the relationship between oxidative stress and hepatosteatosis. Methods: This is an observational study in a tertiary center. Twenty-nine biopsy-proven chronic hepatitis C patients, with no prior anti-viral treatment and persistently elevated serum transaminase levels for 6 months, were included. The control group included 46 healthy subjects. Advanced oxidation protein products and malonyldialdehyde levels were measured. Total radical-trapping antioxidant parameter was calculated. Results: Baseline characteristics were similar in the patient and control groups. In chronic hepatitis C patients, serum levels of advanced oxidation protein products were significantly higher than in the control group (235.0±142.8 vs 116.7±79.5, p<0.001). Serum levels of malonyldialdehyde were also significantly higher than in the control group (9.3±2.1 vs 6.5±1.1, p<0.001). However, there was no significant difference in total radical-trapping antioxidant parameter. The total radical-trapping antioxidant parameter/advanced oxidation protein products index was significantly lower in chronic hepatitis C patients than in healthy controls (p<0.05). There was no significant correlation between advanced oxidation protein products and malonyldialdehyde and hepatosteatosis. Conclusions: We conclude that oxidative stress occurs in chronic hepatitis C, and antioxidant defense mechanisms are inadequate. Serum levels of advanced oxidation protein products and malonyldialdehyde are higher in chronic hepatitis C patients when compared to healthy individuals, and may be useful markers in chronic hepatitis C.

Özet

Amaç: Kronik hepatit C'de oksidatif stres artmış, antioksidan savunma mekanizmaları zayıflamıştır. Bu çalışmanın amacı, kronik hepatit C hastalarını ve sağlıklı kontrolleri oksidatif stres ve antioksidan sistem belirteçleri açısından karşılaştırmak ve oksidatif stres ile hepatosteatoz arasındaki ilişkiyi araştırmaktır. Yöntem: Bu, üçüncü basamak bir merkezde yürütülen gözlemsel bir çalışmadır. Biyopsi ile tanıları doğrulanmış olan, daha önce antiviral tedavi almamış, son 6 aydır ısrarcı serum transaminaz yüksekliği gösteren 29 kronik hepatit C hastası çalışmaya alınmıştır. Kontrol grubu 46 sağlıklı bireyden oluşmaktadır. İleri oksidasyon protein ürünleri'nin ve malonildialdehid'in serum düzeyleri ölçülmüştür. Total radikal tutucu antioksidan parametre hesaplanmıştır. Bulgular: Hasta ve kontrol gruplarında bazal karakteristikler benzerdi. Kronik hepatit C hastalarında, ileri oksidasyon protein ürünleri (235.0±142.8 vs 116.7±79.5, p<0.001) ve malonildialdehid'in (9.3±2.1 vs 6.5±1.1, p<0.001) serum düzeyleri, kontrol grubuna göre anlamlı derecede daha yüksekti (p<0.05). Ancak, total radikal tutucu antioksidan parametre düzeyleri açısından iki grup arasında anlamlı fark gözlenmedi. Kronik hepatit C hastalarında, total radikal tutucu antioksidan parametre/ileri oksidasyon protein ürünleri indeksi, sağlıklı kontrollere göre anlamlı derecede daha düşük bulundu (p<0.05). Hepatosteatoz derecesi ile ileri oksidasyon protein ürünleri ya da malonildialdehid düzeyleri arasında anlamlı ilişki saptanmadı. Sonuç: Sonuç olarak, kronik hepatit C hastalarında oksidatif stres artmıştır ve antioksidan savunma mekanizmaları yetersizdir. Kronik hepatit C hastalarında ileri oksidasyon protein ürünleri'nin ve malonildialdehid'in serum düzeyleri armıştır, bu parametreler kronik hepatit C'de yararlı belirteçler olabilir. Kronik hepatit C hastalarında total radikal tutucu antioksidan parametre/ileri oksidasyon protein ürünleri indeksi, oksidatif stres ve antioksidan savunma sistemi arasındaki dengeyi değerlendirmek açısından faydalı bir parametre olabilir.

🔖

Cite This Article

ÖZENİRLER, S., ERKAN, G. C., GÜLBAHAR, Ö., BOSTANKOLU, Ö., DEMİREL, Ö. Ö., BİLGİHAN, A., AKYOL, G. (2011). Kronik hepatit C hastalarında serum ileri oksidasyon protein ürünleri, malonildialdehid ve total radikal tutucu antioksidan parametre düzeyleri. Turkish Journal of Gastroenterology, Cilt: 22 - Sayı: 1, 47–53. https://ajindex.com/articles/411124

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Boya P, de la Pena A, Beloqui O, et al. Antioxidant status and glutathione metabolism in peripheral blood mononuclear cells from patients with chronic hepatitis C. J Hepatol 1999; 31: 808-14
  2. Levent G, Ali A, Ahmet A, et al. Oxidative stress and antioxidant defense in patients with chronic hepatitis patients before and after pegylated interferon alfa-2b plus ribavirin therapy. J Transl Med 2006; 4: 25
  3. Sies H. Strategies of antioxidant defense. Eur J Biochem 1993; 215: 213-9
  4. Booth AA, Khalifah RG, Hudson BG. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem Biophys Res Commun 1996; 220: 113- 9
  5. Kalousova M, Zima T, Tesar V, et al. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res 2005; 579: 37-46
  6. Kalousova M, Zima T, Tesar V, Stipek S. New markers of advanced damage caused by oxidative and carbonyl stress. Sb Lek 2001; 102: 465-72
  7. Ceriello A, Bortolotti N, Falleti E, et al. Total radical-trapping antioxidant parameter in NIDDM patients. Diabetes Care 1997; 20: 194-7
  8. Esterbauer H. Cytotoxicity and genotoxicity of lipid-oxidation products. Am J Clin Nutr 1993; 57: 779-85
  9. Tanaka H, Fujita N, Sugimoto R, et al. Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C. Br J Cancer 2008; 98: 580-6
  10. Piwowar A, Knapik-Kordecka M, Warwas M. AOPP and its relations with selected markers of oxidative/antioxidative system in type 2 diabetes mellitus. Diabetes Res Clin Pract 2007; 77: 188-92
  11. Witko-Sarsat V, Friedlander M, Capeill鑽e-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-13
  12. Gutteridge JM, Halliwell B. The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem Sci 1989; 15: 129-35
  13. Lindeman JH, van Zoeren-Grobben D, Schrijver J, et al. The total free radical trapping ability of cord blood plasma in preterm and term babies. Pediatr Res 1989; 26: 20–4
  14. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-32
  15. Kalousova M, Skrha J, Zima T. Advanced glycation endproducts and advanced oxidation protein products in patients with diabetes mellitus.